Bacteriophages for treatment of tuberculosis

Patent metadata

Field	Value
Publication number	US-12589127-B2
Application number	US-202418673024-A
Country	US
Kind code	B2
Filing date	May 23, 2024
Priority date	Apr 9, 2021
Publication date	Mar 31, 2026
Grant date	Mar 31, 2026

Abstract

Disclosed are pharmaceutical compositions comprising a combination of five or more phages and a pharmaceutically acceptable carrier, as well as methods of treating, reducing, or preventing a disease caused by Mycobacterium tuberculosis in a mammal, methods of treating an antibiotic resistant infection in a mammal, and methods of treating, reducing, or preventing activation of a latent disease caused by M. tuberculosis.

First claim

The invention claimed is:

1 . A pharmaceutical composition comprising a combination of five or more phages selected from the group consisting of D29, AdephagiaΔ41Δ43, ZoeJΔ45, FionnbharthΔ47, FionnbharthΔ45Δ47, CG-REM-1, CG-REM-2, Fred313cpm-1, Fred313cpm-1Δ33, MuddyHRM N0052 -1, Muddy_HRM N0157 -2, and DS6A
and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is selected from the group consisting of water, saline, propylene glycol, polyethylene glycol, alcohol, and any combination thereof.

2 . The pharmaceutical composition of claim 1 , wherein the combination of five or more phages is selected from the group consisting of:
(a) D29; (b) AdephagiaΔ41Δ43; (c) FionnbharthΔ45Δ47; (d) CG-REM-1; (e) CG-REM-2; (f) Fred313cpm-1Δ33; and (g) Muddy_HRM N0157 -2.

3 . The pharmaceutical composition of claim 1 , wherein the combination of five or more phages consist of:
(a) D29; (b) AdephagiaΔ41Δ43; (c) FionnbharthΔ45Δ47; (d) Fred313cpm-1Δ33; (e) Muddy_HRM N0157 -2; and (f) optionally one or more of, ZoeJΔ45, FionnbharthΔ47, CG- REM-1, CG-REM-2, Fred313cpm-1, MuddyHRM N0052 -1, and DS6A.

4 . A method of treating a disease caused by Mycobacterium tuberculosis in a mammal comprising administering the pharmaceutical composition of claim 1 to the mammal, thereby treating the disease in the mammal.

5 . The method of claim 4 , wherein the disease caused by Mycobacterium tuberculosis is one or more of tuberculosis, tubercular meningitis, and bone and joint tuberculosis.

6 . The method of claim 4 , wherein the pharmaceutical composition is administered in combination with one or more antibiotics.

7 . The method of claim 6 , wherein the antibiotic is selected from the group consisting of isoniazid, ethambutol, pyrazinamide, rifampicin, streptomycin, amikacin, kanamycin, ciprofloxacin, delamanid, bedaquiline, and any combination thereof.

8 . The method of claim 6 , wherein the length of treatment is reduced as compared to the length of treatment with one or more antibiotics alone.

9 . The method of claim 8 , wherein the length of treatment is 4 months.

10 . The method of claim 8 , wherein the length of treatment is 3 months.

11 . The method of claim 8 , wherein the length of treatment is 2 months.

12 . The method of claim 8 , wherein the length of treatment is 1 month.

13 . The method of claim 4 , wherein the pharmaceutical composition is administered intravenously.

14 . The method of claim 4 , wherein the pharmaceutical composition is administered as an aerosol.

15 . The method of claim 4 , wherein the mammal is a human.

16 . A method of treating an antibiotic resistant infection in a mammal comprising administering the pharmaceutical composition of claim 1 to the mammal.

17 . The method of claim 16 , wherein the antibiotic resistant infection is pulmonary tuberculosis.

18 . The method of claim 16 , wherein the antibiotic resistant infection is caused by an infectious agent that is resistant to an antibiotic selected from the group consisting of isoniazid, rifampin, pyrazinamide, ethambutol, rifapentine, moxifloxacin, and any combination thereof.

19 . A method of treating activation of a latent disease caused by Mycobacterium tuberculosis in a mammal, comprising administering the pharmaceutical composition of claim 1 to the mammal, thereby treating the activation of the latent disease.

20 . The pharmaceutical composition of claim 1 , wherein the combination of five or more phages consists of:
(a) D29; (b) AdephagiaΔ41Δ43; (c) FionnbharthΔ45Δ47; (d) Fred313cpm-1Δ33; and (e) Muddy_HRM N0157 -2.

Assignees

• Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education

Inventors

• Hatfull Graham F
• Guerrero Carlos Andrés
• Dedrick Rebekah Marie

Classifications

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K9/0073

  Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M) · CPC title

• A61P31/06 Primary

  for tuberculosis · CPC title

• C12N2795/10332

  Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent · CPC title

• C12N2795/10321

  Viruses as such, e.g. new isolates, mutants or their genomic sequences · CPC title